The incomplete Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT)

[1]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[2]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[3]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[4]  H. Dargie.  Design and methodology of the CAPRICORN trial — a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction , 2000, European journal of heart failure.

[5]  N. Freemantle,et al.  Are beta‐blockers effective in patients who develop heart failure soon after myocardial infarction? A meta‐regression analysis of randomised trials , 2000, European journal of heart failure.

[6]  J. Cleland,et al.  The LIDO, HOPE, MOXCON and WASH studies , 1999 .

[7]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[8]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[9]  R. Willette,et al.  Evaluation of Intrinsic Sympathomimetic Activity of Bucindolol and Carvedilol in Rat Heart , 1998, Pharmacology.

[10]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[11]  L. Køber,et al.  Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. , 1995, The American journal of cardiology.

[12]  L. Køber,et al.  An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. , 1994, European heart journal.

[13]  P. Andersen,et al.  Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. , 1992, Cardiology.

[14]  R. Hershberger,et al.  Mechanism of Action of Bucindolol in Human Ventricular Myocardium , 1990, Journal of cardiovascular pharmacology.

[15]  J. Berning,et al.  Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. , 1990, The American journal of cardiology.

[16]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[17]  C. Ansell.  Letter: Milk for babies. , 1975, Lancet.

[18]  P. Snow.  Effect of propranolol in myocardial infarction. , 1965, Lancet.